{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:07:50Z","timestamp":1792807670099,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Myasthenia gravis (MG) is not commonly covered in pharmacy school curricula. However, many medications that have been reported to cause exacerbations of MG are among the top 200 most prescribed drugs. The purpose of this therapeutic update is to provide pharmacists with a general understanding of the pathophysiology and treatment of MG and describe common medications with the potential to cause new onset or acute worsening of this disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>MG is an autoimmune disorder in which patients develop autoantibodies to a component of the neuromuscular junction, most frequently the acetylcholine receptor, resulting in impairment of skeletal muscle contraction. Although MG is not highly prevalent, there are up to 60,000 individuals with MG in the US, making it a disease that many pharmacists will likely encounter at least once in their career. Immunosuppressant medications and acetylcholinesterase inhibitors are the mainstays of treatment, although there is limited evidence as to which agents are most efficacious. Medications that activate the immune system, such as immune checkpoint inhibitors, may cause new onset of disease, while those with actions on the neuromuscular junction, such as macrolides and fluoroquinolones, can cause acute worsening of disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MG, although not frequently covered in pharmacy school curricula, is a disease state for which it is not uncommon for pharmacists to provide care. Treatment tends to be patient specific, and evidence is often weak. Many medications that cause new onset or worsening of MG are among the most prescribed. Key classes of medications to use with caution include macrolides, fluoroquinolones, \u03b2-blockers, and magnesium.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxac343","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T10:49:13Z","timestamp":1668422953000},"page":"249-257","source":"Crossref","is-referenced-by-count":5,"title":["Myasthenia gravis: What does a pharmacist need to know?"],"prefix":"10.1093","volume":"80","author":[{"given":"Morgan","family":"Marriott","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, and University of Michigan College of Pharmacy , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Schwery","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, and University of Michigan College of Pharmacy , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, and University of Michigan College of Pharmacy , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"26","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jac5.1178","article-title":"2019 update to the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit","volume":"3","author":"Flannery","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"issue":"7","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"2023022113000431600_","article-title":"Clinical overview of MG.","author":"Howard","year":"2015"},{"issue":"1","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2023022113000431600_","author":"BioRender"},{"key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"6","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000507853","article-title":"Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China","volume":"83","author":"Feng","year":"2020","journal-title":"Eur Neurol"},{"issue":"12","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"issue":"5","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","article-title":"Myasthenia gravis: new developments in research and treatment","volume":"30","author":"Evoli","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"issue":"4","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J Clin Neurol"},{"issue":"3","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis","volume":"56","author":"Myasthenia Gravis Clinical Study Group.","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"issue":"12","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory myasthenia gravis (REGAIN): a phase 3, randomized, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with myasthenia gravis (ADAPT): a multicentre, randomized, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guideline for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"key":"2023022113000431600_","author":"BioRender.com."},{"issue":"1","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"727010","DOI":"10.3389\/fonc.2021.727010","article-title":"Neuromuscular complications of targeted anticancer agents: can tyrosine kinase inhibitors induce myasthenia gravis? Getting answers from a case report up to a systematic review","volume":"11","author":"Ziogas","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"10","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA Adverse Event Reporting System and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"issue":"8","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s10072-020-04387-5","article-title":"Exacerbation of myasthenia gravis after amoxicillin therapy: a case series","volume":"41","author":"Vacchiano","year":"2020","journal-title":"Neurol Sci"},{"issue":"4","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jocn.2021.11.010","article-title":"Is myasthenia gravis a contraindication for botulinum toxin?","volume":"95","author":"Ma","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J Clin Neurol"},{"issue":"7","key":"2023022113000431600_","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac343\/48343810\/zxac343.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/5\/249\/49285176\/zxac343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/5\/249\/49285176\/zxac343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T00:15:27Z","timestamp":1678580127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/5\/249\/6827110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac343","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,14]]}}}